PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

Pfizer (PFE) will report its second-quarter 2024 earnings on Jul 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.22 billion and 45 cents per share ...

As regards Pfizer, oncology sales ... of Pfizer’s diversified portfolio of drugs, particularly oncology, ... currently trade at 8.24 forward earnings, higher than 7.41 for Pfizer.

Pfizer's Q4 Earnings Beat Estimates, ... sales of some key drugs like Prevnar, Xeljanz and Ibrance and new RSV vaccine, ... Sales of Oncology rose 27% to $4.06 billion.

Estimates for Vertex Pharmaceuticals’ 2022 earnings have gone up from $14.52 to $14.56 per share, while those for 2023 have increased from $15.31 to $15.35 per share over the past 30 days.

Pfizer's Vyndaqel heart disease drug - which earned ~$1.13bn revenues in Q1 2024, is also facing expiring patents - in 2025 in the US - as is Xeljanz, a former $2.5bn per annum autoimmune therapy ...

Oncology’s Contribution To Pfizer’s EPS. We use adjusted net income margin of around 32%, similar to that of Pfizer overall, to arrive at $0.36 contribution to Pfizer’s total earnings.

The New York-based drug company (PFE) had net income of $4.465 billion, or 78 cents a share, for the quarter, after a loss of $2.382 billion, or 42 cents a share, in the year-earlier period.

Pfizer's earnings estimates beat expectations on Wednesday, due to the company's growing oncology business and slower-than-expected sales declines of its Covid-19 antiviral pill Paxlovid.

Pfizer Chief Executive Albert Bourla is feeling more confident in his $43 billion acquisition of Seagen – thanks to the buzz around antibody-drug conjugate cancer drugs. “I feel way more ...